Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases

NN Rahbari, D Kedrin, J Incio, H Liu, WW Ho… - Science translational …, 2016 - science.org
The survival benefit of anti–vascular endothelial growth factor (VEGF) therapy in metastatic
colorectal cancer (mCRC) patients is limited to a few months because of acquired …
被引用次数：220 相关文章

Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases.

NN Rahbari, D Kedrin, J Incio, H Liu… - Science …, 2016 - search.ebscohost.com
The article presents a study which examined the effects of antiangiogenic or anti-vascular
endothelial growth factor (VEGF) therapy on the composition of both collagenous and …
[PDF] academia.edu

[PDF][PDF] Anti-VEGF Therapy Induces ECM Remodeling and Mechanical Barriers to Therapy in Colorectal Cancer Liver Metastases

NN Rahbari - Science Translational Medicine, 2016 - academia.edu
The survival benefit of anti–vascular endothelial growth factor (VEGF) therapy in metastatic
colorectal cancer (mCRC) patients is limited to a few months because of acquired …

Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases

NN Rahbari, D Kedrin, J Incio, H Liu, WW Ho, HT Nia… - 2016 - dspace.mit.edu
The survival benefit of anti-vascular endothelial growth factor (VEGF) therapy in metastatic
colorectal cancer (mCRC) patients is limited to a few months because of acquired …

Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases.

NN Rahbari, D Kedrin, J Incio, H Liu… - Science Translational …, 2016 - europepmc.org
The survival benefit of anti–vascular endothelial growth factor (VEGF) therapy in metastatic
colorectal cancer (mCRC) patients is limited to a few months because of acquired …

[引用][C] Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases

NN Rahbari, D Kedrin, J Incio, H Liu, WW Ho… - Science Translational …, 2016 - cir.nii.ac.jp
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal
cancer liver metastases | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
[HTML] nih.gov

[HTML][HTML] Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases

NN Rahbari, D Kedrin, J Incio, H Liu… - Science translational …, 2016 - ncbi.nlm.nih.gov
The survival benefit of anti–vascular endothelial growth factor (VEGF) therapy in metastatic
colorectal cancer (mCRC) patients is limited to a few months because of acquired …

Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases

NN Rahbari, D Kedrin, J Incio, H Liu… - Science …, 2016 - pubmed.ncbi.nlm.nih.gov
The survival benefit of anti-vascular endothelial growth factor (VEGF) therapy in metastatic
colorectal cancer (mCRC) patients is limited to a few months because of acquired …

Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases

NN Rahbari, D Kedrin, J Incio, H Liu… - Science …, 2016 - snucm.elsevierpure.com
The survival benefit of anti-vascular endothelial growth factor (VEGF) therapy in metastatic
colorectal cancer (mCRC) patients is limited to a few months because of acquired …

Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases.

NN Rahbari, D Kedrin, J Incio, H Liu… - Science Translational …, 2016 - europepmc.org
The survival benefit of anti–vascular endothelial growth factor (VEGF) therapy in metastatic
colorectal cancer (mCRC) patients is limited to a few months because of acquired …